> Company 2013/01/23 : Watson Acquires Uteron Pharma Read more 2012/05/2 : Uteron Pharma is contemplating a public offering to finance the (...) Read more 2012/04/24 : Professor Jean-Michel Foidart has been awarded the Bologne-Lemaire (...) Read more Newsletter subscribe Background About Uteron Pharma SPRL Uteron Pharma sprl is a Research & Development oriented company and a subsidiary of Actavis plc. Actavis plc (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand, branded generic, Over-the Counter (OTC) and biosimilar products. Uteron Pharma sprl is designated as one of Actavis’ Centre of Excellence for women’s health delivering product development, cGMP manufacturing of Levosert™ hormonal intra-uterine device and quality & regulatory expertise from a custom-designed facility located in Liège, Belgium. The company has successfully developed Levosert™ (levonorgestrel-releasing Intra-Uterine Device), and is currently developing Estetrol (E4) Combination Oral Contraception, a non-invasive adjunctive In Vitro Fertilization selection assay and an early stage treatment for high grade cervical lesions. About Actavis plc Actavis plc (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand, branded generic, Over-the Counter (OTC) and biosimilar products. The Company has global headquarters in Dublin, Ireland and Administrative Headquarters in Parsippany, New Jersey, USA. The new Actavis plc is a powerful combination of the highly successful and previously separate Actavis, Inc. (NYSE:ACT) and Warner Chilcott plc (NASDAQ: WCRX). Operating as Actavis Pharma, our generic, branded generic, legacy brands and Over-the-Counter (OTC) business markets more than 750 products globally through operations in more than 60 countries. Actavis Specialty Brands is a global branded specialty pharmaceutical business focused principally in the Women’s Health, Urology, Gastroenterology and Dermatology therapeutic categories. Actavis is committed to developing and marketing biosimilar products in Women’s Health, Oncology and other therapeutic categories. Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, and includes Anda, Inc., a U.S. pharmaceutical product distributor. Actavis develops and out-licenses generic pharmaceutical products to customers in more than 100 countries outside of the U.S. through its Medis third-party business. Discover our job opportunities © 2011 Uteron Pharma - Legal - Privacy policy Designed and Powered by Lusis Communication Company Background History Location Management team Contact us Products Levosert™ E4/Progestin OC Diafert™ Colvir Production Market Newsroom